New Insights Into Major Depressive Disorder

Key Takeaways

• Clinical rationale centers on addressing partial response by adding an agent with a distinct mechanism while maintaining antidepressant backbone, with early evaluation of benefit and tolerability.
• Comparative data help differentiate adjunctive options on onset, effect size, and discontinuation, enabling more individualized decisions for patients with comorbid anxiety, insomnia, or bipolar spectrum features.
• Payer pathways commonly rely on step therapy and prior authorization, prioritizing generics, documenting failed trials, and requiring monitoring plans for weight, lipids, glucose, EPS, and sedation.
• Correll underscores integrating metabolic and neurologic risk mitigation, shared decision‑making, and adherence strategies to reduce relapse and downstream utilization, aligning clinical outcomes with value-based metrics.